In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

DiObex closes $24mm Series B round

Executive Summary

DiObex (therapeutics for metabolic disorders) raised $24mm in its Series B financing round led by Inventages Venture Capital with additional participation from new investors Mitsui Ventures and Pac-Link BioVentures, and returning shareholders Domain Associates, Pequot Ventures, and Sofinnova Ventures. The proceeds will be used to move the company's two lead compounds--DIO901 for Type I diabetes and DIO902 for Type II diabetes--through Phase II. A member each from Inventages, Mitsui, Sofinnova (chairman), and Pac-Link (observer) will join DiObex's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies